Ultragenyx (RARE) Q4 2025 earnings review
Restructuring and Regulatory Errors Overshadow Revenue Beat
Ultragenyx delivered a strong Q4 with $207M in revenue (+25% YoY), driven by Crysvita in Latin America. However, the narrative is complicated by two major developments: a sloppy regulatory execution regarding UX111 (receiving an Incomplete Response Letter on a resubmission) and a 10% workforce reduction. While management reiterated their 2027 profitability goal, the FY26 revenue guidance implies a significant growth deceleration (8-13%) compared to FY25 (20%). The company is cutting costs to manufacture profitability, as organic top-line growth alone is insufficient to close the gap.
🐂 Bull Case
The Latin America/Türkiye region is outperforming expectations, with Crysvita product sales up 31% YoY in FY25. Q4 alone saw $40M from this region, nearly doubling the $22M from Q4 24.
The announced 10% workforce reduction and flat-to-down OpEx guidance for 2026 demonstrates management is serious about the 2027 profitability target, moving from 'growth at all costs' to fiscal prudence.
🐻 Bear Case
Received an Incomplete Response Letter (IRL) for the UX111 BLA resubmission. Following a CRL in July 2025, failing to submit a complete response package is a significant operational red flag that suggests internal disorganization.
FY26 revenue guidance of $730-$760M implies ~10.7% growth at the midpoint, a sharp slowdown from the 20% growth achieved in FY25. This pressures the valuation if the pipeline does not deliver immediate commercial wins.
⚖️ Verdict: ⚪
Neutral. The base business is healthy, but the growth rate is cooling significantly. The IRL for UX111 is an unforced error that shakes confidence in regulatory execution just as the company approaches critical PDUFA dates.
Key Themes
Regulatory Execution Failure (UX111)
Management disclosed receiving an Incomplete Response Letter (IRL) regarding the UX111 (Sanfilippo syndrome) BLA resubmission. This follows a Complete Response Letter (CRL) received in July 2025. Failing to provide a complete package on a resubmission is a rare and worrying administrative failure that delays potential approval and raises questions about the regulatory team's competence.
Strategic Restructuring
Ultragenyx initiated a restructuring plan involving a 10% workforce reduction (~130 employees) to align resources with value drivers. While necessary for the 2027 profitability goal, this creates near-term organizational disruption and incurs ~$50M in restructuring charges in 2026.
Top-Line Deceleration
FY26 revenue guidance ($730-760M) suggests the hyper-growth phase is pausing. The midpoint implies ~10.7% growth, down from 20% in FY25. Without a new commercial launch in early 2026, the company is relying heavily on existing products where improved ordering patterns in Brazil are partially offset by maturity in other markets.
Crysvita Latin America Strength
Crysvita continues to outperform in emerging markets. FY25 product sales in Latin America and Türkiye hit $177M, up 31% YoY. This high-margin revenue stream is becoming a critical pillar of the company's financials, helping offset slower royalty growth in mature markets (US/EU royalty revenue +10%).
Evkeeza Commercial Ramp
Evkeeza revenue grew 84% in FY25 to $59M (up from $32M), with Q4 revenue up 70% YoY. Demand is building following launches in territories outside the US, diversifying the revenue base away from total reliance on Crysvita.
DTX401 Regulatory Progress
Despite the UX111 stumble, the DTX401 (GSDIa) program is moving forward. The BLA rolling submission was completed in December 2025, with a PDUFA date anticipated in Q3 2026. This represents the next major commercial leg for the company.
Other KPIs
Narrowed slightly from $133M in 24Q4. While revenue grew $42M YoY, OpEx increased $34M, demonstrating that operating leverage is still elusive. The restructuring is aimed squarely at fixing this dynamic.
Cash, equivalents, and marketable securities. With a quarterly net loss of ~$129M, this provides runway into 2027, but the margin for error is slim without the announced cost reductions.
Stable/Decelerating. Revenue was essentially flat sequentially (Q3: $32M implied, actual Q3 report listed $24M in call summary but Q4 text implies cumulative). YoY growth was only 3.2% (vs $31M in 24Q4), indicating this product may be reaching saturation in current markets.
Guidance
Decelerating. Implies 8-13% growth, significantly lower than the 20% growth seen in FY25. The company cites 'growing underlying demand' offset by ordering patterns in Brazil.
Stable. Midpoint implies ~6% growth over FY25 ($481M). This confirms Crysvita is entering a mature growth phase, shifting the burden of double-digit growth to the pipeline.
Accelerating. Midpoint implies ~9% growth vs FY25 ($96M), an improvement over the 3% growth seen in Q4. Suggests confidence in re-accelerating patient uptake.
Reversing. OpEx grew ~10% in FY25 ($1.2B vs $1.1B). The guidance for flat/down expenses includes the impact of the 10% workforce reduction and is the primary mechanism for narrowing losses.
Key Questions
UX111 IRL Details
An Incomplete Response Letter on a resubmission is highly unusual. What specific documents were missing, and does this reflect a deeper issue with the quality of the CMC data generated by the manufacturing team?
Restructuring Impact on Launch
With a 10% workforce reduction, how are you ensuring the commercial organization remains fully staffed to support the potential launch of DTX401 in late 2026?
Dojolvi Stagnation
Dojolvi growth slowed to 3% YoY in Q4. What specific dynamics caused this slowdown, and what gives you confidence in the re-acceleration implied by the $100-$110M guidance for FY26?
Brazil Volatility
You noted 'expected timing of ordering patterns in Brazil' as a headwind for FY26. Can you quantify the expected impact of this volatility on Q1 vs Q2 results?